T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

Immunotherapy has shown promising effect for non-small cell lung cancer (NSCLC) patients. Yet the biomarkers for predicting immunotherapy efficiency are still lacking. We tested 139 surgical resected NSCLC primary tumor samples from Medical University of Gdansk, Poland, for T cell immunoglobulin and mucin-domain containing-3 (TIM-3) level by immunohistochemistry (IHC), analyzed the expression of TIM-3 protein on NSCLC tumor cells and tumor infiltrating lymphocytes (TILs). TIM-3 on TILs was correlated with programmed cell death protein-1 (PD-1) on TILs (correlation coefficient =0.346, P<0.001) and programmed cell death protein-ligand 1 (PD-L1) on TILs (correlation coefficient =0.313, P<0.001), PD-L1 level on tumor cells (correlation coefficient =0.255, P=0.002), TIM-3 level on tumor cells (correlation coefficient =0.262, P=0.002) and TIL percentage (correlation coefficient =0.172, P=0.043). TIM-3 level on tumor cells only had correlation with PD-L1 level (correlation coefficient =0.170, P=0.045). High level of TIM-3 on TILs indicated shorter recurrence-free survival (RFS) and overall survival (OS) (RFS 1.800 years, 95% CI, 1.230-2.370 vs. 0.870 years, 95% CI, 0.212-1.528, P=0.048) (OS 2.960 years, 95% CI, 2.268-3.652 vs. 1.080 years, 95% CI, 0.228-1.932, P=0.034). TIM-3 is expressed on NSCLC tumor cells and TILs in all NSCLC pathological type. TIM-3 level on TILs had correlation with PD-1 and PD-L1 level. NSCLC patients with high TIM-3 level on TILs were more likely to have poor prognosis.

Jia K ，He Y ，Dziadziuszko R ，Zhao S ，Zhang X ，Deng J ，Wang H ，Hirsch FR ，Zhou C ，Yu H ，Zhang L ... -  《-》

Galectin-9 in non-small cell lung cancer.

Lung cancer has the highest incidence and fatality among all cancers. Our research analyzed the expression of galectin-9 on non-small cell lung cancer (NSCLC) tumor cells and tumor infiltrating lymphocytes (TILs). We analyzed the expression level of galectin-9 protein in 136 NSCLC primary tumor samples by immunohistochemistry (IHC). We tested 136 surgical resected primary NSCLC tumor tissues for galectin-9 from Medical University of Gdansk, Poland. We found that on tumor cells, galectin-9 level only had correlation with T cell immunoglobulin and mucin-domain containing-3 (TIM-3) level (Correlation Coefficient = 0.360, p < 0.001). On TILs, galectin-9 level had broad connections with other checkpoints including programmed cell death protein-1 (PD-1) (Correlation Coefficient = 0.332, p < 0.001), programmed cell death-ligand 1 (PD-L1) (Correlation Coefficient = 0.247, p = 0.004) and TIM-3 (Correlation Coefficient = 0.350, p < 0.001). Interestingly, galectin-9 level on TILs also had positive relation with PD-L1 level on tumor cells (Correlation Coefficient = 0.278, p = 0.001), galectin-9 level on tumor cells (Correlation Coefficient = 0.181, p = 0.035) and TIL percentage (Correlation Coefficient = 0.236, p = 0.006). High level of galectin-9 on TILs indicated shorter RFS (recurrence-free survival) (RFS 1.82 years, 95% CI 0.795-2.845 vs. 0.67 years, 95% CI 0.086-1.254, P = 0.033). Patients with galectin-9 positive tumor cells display longer overall survival (OS) (1.76 years, 95% CI 0.222-3.298 vs. 3.10 years, 95% CI 2.662-3.538, P = 0.039) CONCLUSIONS: We found galectin-9 expression on both NSCLC tumor cells and TILs. Galectin-9 expression was found in all NSCLC pathological type. Galectin-9 level on TILs had correlation with TIM-3, PD-1 and PD-L1 level. On tumor cells, galectin-9 level had correlation with TIM-3 level. Patients with low galectin-9 level on tumor cells or high galectin-9 level on TILs were more likely to have poor prognosis.

He Y ，Jia K ，Dziadziuszko R ，Zhao S ，Zhang X ，Deng J ，Wang H ，Hirsch FR ，Zhou C ... -  《-》

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

He Y ，Rozeboom L ，Rivard CJ ，Ellison K ，Dziadziuszko R ，Yu H ，Zhou C ，Hirsch FR ... -  《MEDICAL SCIENCE MONITOR》

T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.

Byun KD ，Hwang HJ ，Park KJ ，Kim MC ，Cho SH ，Ju MH ，Lee JH ，Jeong JS ... -  《-》

OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

He Y ，Zhang X ，Jia K ，Dziadziuszko R ，Zhao S ，Deng J ，Wang H ，Hirsch FR ，Zhou C ... -  《-》